AOP-Wiki

API

All KERs

Showing 101 to 125 of 3158 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

1432	1323: Decreased, intracellular serotonin	1324: Decreased, packaged serotonin	Apr 14, 2017	Apr 14, 2017	4 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 221: Mental stress to depression 222: Mental stress to agitation 226: SSRI (Selective serotonin reuptake inhibitor) to hypertension
1433	1324: Decreased, packaged serotonin	1325: Decreased, synaptic release	Apr 14, 2017	Apr 14, 2017	4 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 221: Mental stress to depression 222: Mental stress to agitation 226: SSRI (Selective serotonin reuptake inhibitor) to hypertension
1434	1325: Decreased, synaptic release	1347: Decreased, extracellular serotonin	Apr 14, 2017	Apr 14, 2017	4 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 222: Mental stress to agitation 226: SSRI (Selective serotonin reuptake inhibitor) to hypertension 221: Mental stress to depression
1447	1329: Reduce expression, BDNF	1330: Decreased, neuroplasticity	Apr 14, 2017	Apr 14, 2017	4 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 222: Mental stress to agitation 225: Serotonin transporter activation to agitation 224: Serotonin transporter activation to depression
1449	1330: Decreased, neuroplasticity	1346: Increased, depression	Apr 14, 2017	Apr 14, 2017	4 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 221: Mental stress to depression 224: Serotonin transporter activation to depression 604: Binding of Alpha 1-Adrenergics to Agonists Leading to Depression
984	18: Activation, AhR	947: Increase, Early Life Stage Mortality	Nov 29, 2016	Apr 14, 2019	4 AOPs 150: Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF 21: Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 456: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity 455: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development
1002	990: Increase, Incomplete ecdysis	350: Increase, Mortality	Nov 29, 2016	Dec 3, 2016	4 AOPs 466: Doda decarboxylase leading to mortality 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade 343: Ecdysone receptor antagonism leading to mortality via mis-timed ecdysone receptor-responsive nuclear receptor cascade
1146	559: Activation, Nicotinic acetylcholine receptor	341: Impairment, Learning and memory	Nov 29, 2016	Dec 3, 2016	4 AOPs 77: Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 87: Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure 88: Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste 89: Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure
1676	709: Increase, Cytotoxicity (renal tubular cell)	814: Occurrence, Kidney toxicity	Oct 25, 2017	Mar 8, 2022	4 AOPs 256: Inhibition of mitochondrial DNA polymerase gamma leading to kidney toxicity 257: Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity 258: Renal protein alkylation leading to kidney toxicity 437: Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity
1690	1392: Increase, Oxidative Stress	55: Cell injury/death	Nov 9, 2017	Feb 7, 2020	4 AOPs 17: Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress
1702	1495: Interaction with the lung cell membrane	1496: Increased proinflammatory mediators	Jan 5, 2018	Jun 22, 2026	3 AOPs 173: Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis 451: Interaction with lung resident cell membrane components leads to lung cancer 237: Substance interaction with lung resident cell membrane components leading to atherosclerosis via acute phase response
1317	619: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	1142: Increased, valve movement	Jan 13, 2017	Jan 13, 2017	3 AOPs 97: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline 204: 5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase
1318	619: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)	621: Increase, cilia movement	Jan 13, 2017	Jan 13, 2017	3 AOPs 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline 204: 5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase
1333	626: Increased, serotonin (5-HT)	621: Increase, cilia movement	Jan 30, 2017	Jan 30, 2017	3 AOPs 204: 5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
1346	988: Decrease, Circulating ETH	1266: Decrease, Circulating CCAP	Feb 9, 2017	Feb 9, 2017	3 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade 343: Ecdysone receptor antagonism leading to mortality via mis-timed ecdysone receptor-responsive nuclear receptor cascade
1347	1266: Decrease, Circulating CCAP	1267: Decrease, Ecdysis motor program activity	Feb 9, 2017	Feb 9, 2017	3 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade 343: Ecdysone receptor antagonism leading to mortality via mis-timed ecdysone receptor-responsive nuclear receptor cascade
1446	1328: Inactivated, 5-HTR	1329: Reduce expression, BDNF	Apr 14, 2017	Apr 14, 2017	3 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 225: Serotonin transporter activation to agitation 224: Serotonin transporter activation to depression
1448	1330: Decreased, neuroplasticity	1345: Increased, agitation	Apr 14, 2017	Apr 14, 2017	3 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 222: Mental stress to agitation 225: Serotonin transporter activation to agitation
1458	1355: Activated, membrane depolarization	1362: Increased, hippocampal hyperdepolarization	Apr 14, 2017	Apr 14, 2017	3 AOPs 215: Molecular events lead to epilepsy 230: presynaptic neuron 1 activation to epilepsy 231: presynaptic neuron 2 repression to epilepsy
1524	1397: Increased, serotonin transporter activity	1398: Increased, intracellular serotonin	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1525	1398: Increased, intracellular serotonin	1399: Increased, packaged serotonin	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1526	1399: Increased, packaged serotonin	1400: Increased, synaptic release	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1527	1400: Increased, synaptic release	1320: Increased, extracellular serotonin	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1528	1397: Increased, serotonin transporter activity	1347: Decreased, extracellular serotonin	Jun 1, 2017	Jun 1, 2017	3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
1567	317: Altered, Cardiovascular development/function	947: Increase, Early Life Stage Mortality	Jun 9, 2017	Mar 23, 2018	3 AOPs 150: Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF 21: Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 456: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity

Key Event Relationships (KERs)

All KERs